Search academic texts

Information × Registration Number 0222U003717, 0119U000579 , R & D reports Title Identify ways to reduce the disability of patients with giant cell disease of bones on the basis of targeted therapy and optimization of surgical treatment popup.stage_title Head Diedkov Anatolii H., Registration Date 25-05-2022 Organization National Cancer Institute popup.description2  Object of study: giant bone tumor. Research methods: clinical (questionnaires), laboratory, radiological, morphological and methods of statistical processing of results. The aim is to improve organ-preserving tactics of treatment of patients with giant cell bone tumors by developing indications for targeted therapy, selection of optimal surgical tactics based on assessment of anatomical and functional status, and medical and economic properties. Clinical and economic evaluation of alternative treatment technologies (patients after extensive resections with endoprosthetics and excochleation with TT) was performed using the method of "cost / effectiveness". During the analysis for each of the technologies was calculated cost ratio per 1 effectively treated patient with a giant cell tumor of the distal femur, which took into account the cost, in this case, of implants, drugs and dressings, the relative cost of one bed-day . The incremental indicator (ICER) was used as a criterion of economic efficiency, which reflects the amount of additional financial investments required to achieve full recovery of limb function (MSTS - 90% and above). The results show that the use of Denosumab in the treatment of patients with giant cell tumors of the knee joint allows for 5 years to improve knee function by 72% compared to standard therapy, while the additional cost of the patient for innovative treatment with denosunab will exceed the cost required. standard treatment for UAH 56,498.88. per year or in (4 708, 24 per month = 1/3 of the average monthly PA). Compared to the selected solvency threshold, UAH 160,800 per unit of efficiency is calculated by ICER, UAH 78,385 / 100% of limb functionality is much lower than the selected solvency threshold, which indicates the economic feasibility of using denosumab. This means that this method of treatment is economically affordable for patients in Ukraine. Product Description popup.authors Boichuk Serhii I. Kostyuk Victor Yu. Maksymenko Bohdan V. popup.nrat_date 2022-05-25 Close